The American Red Cross Relieves VDI Printing Pains with UniPrint Infinity
Ahead of their appearance at the VMworld US trade show in Las Vegas, Print Virtualization software provider UniPrint.net Corp announced today the release of their latest case study: The American Red Cross (ARC). With a national network of more than 300 chapters, The American Red Cross is one of the world’s premier charitable organizations made up of workers and volunteers providing humanitarian relief both in the United States and abroad.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170824005757/en/
The ARC’s IT infrastructure includes more than 20,000 employees and 300,000 volunteers in offices, remote locations, connecting from home, or in the field in disaster zones. In 2015, their End Use Technologies Solutions (EUTS) team began their search for a virtual workspace solution that would give their users access to applications, data, and resources from any location. Immediately, printing was identified as an issue, both due to driver incompatibility being common in VDI environments, and due to the tediousness of Group Policies for printer mapping with so many remote locations and devices.
They were also looking to eliminate hardware and consolidate remote site resources back to the data center, which posed potential bandwidth issues. Additionally, the EUTS team intended on instituting a BYOD (bring-your-own-device) model which would also require a stable print management solution.
With their implementation of UniPrint Infinity™ The ARC was able to solve all of their printing challenges with one streamlined solution. The patented PDF-based Universal Printer Driver (UPD) solved the issue of printer driver incompatibility and eliminated the need for repeated and frequent vendor driver updates. Printer mapping issues were also solved with the PrintPAL utility, which allows administrators to implement broad printing policies with only a few clicks.
There was also the added benefit of reduced call volume to The ARC’s third-party service desk. Adam Flowers, Lead Solutions Architect, remarked:
“There was a reduction in helpdesk calls for printing related issues as we made improvements to our environment with UniPrint […] UniPrint saved us lots of time and headaches, and it really made our techs available to deal with higher priority issues.”
Other benefits included the flexibility of BYOD printing, as well as a reduction in bandwidth usage (and therefore a reduction in cost). UniPrint Infinity has not only helped The American Red Cross funnel more resources back into the community, but also helped staff spend less time on printing and more time focusing on making the world a better place.
“The UniPrint Infinity™ suite allows us to adapt to whatever situation our people may be in,” said Flowers. “There’s nothing we’ve been asked to do that UniPrint can’t handle.”
- Universal Printer Driver (UPD) solves incompatibility issues and reduces helpdesk calls
- PrintPAL technology eliminates the need for mapping through Group Policies
- Reduces overhead cost through printer server consolidation
- High Availability (HA) module provides enterprise wide redundancy and fault tolerance
- Resolves bandwidth issues using PDF compression to compress and encrypt print jobs
- Provides local and remote users with seamless, stable, and secure printing from any device to the nearest available printer
To learn more, check out our video interview with Adam Flowers on how UniPrint Infinity transformed American Red Cross’ IT workflow, and don’t forget to stop by Booth 1724 at VMworld US in Las Vegas Aug. 27-31 to meet the UniPrint team!
About UniPrint.net Corp
UniPrint.net Corp. is an innovative leader in printing virtualization. Their patented PDF-based software, UniPrint Infinity™, is the industry’s first truly secure enterprise printing solution for any computing environment. UniPrint Infinity replaces all manufacturer printer drivers with a single Universal Printer Driver (UPD) to promote faster, more efficient printing. Both UniPrint™ and UniPrint Infinity™ are the trademarks of UniPrint.net. All other trademarks and registered trademarks are properties of their respective owners.
Kate Bradford, 416-503-9800 x8258
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme